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Subclinical Myocardial Necrosis and Cardiovascular Risk in
Stable Patients Undergoing Elective Cardiac Evaluation
W.H. Wilson Tang, Yuping Wu, Stephen J. Nicholls, Danielle M. Brennan, Michael Pepoy,
Shirley Mann, Alan Pratt, Frederick Van Lente, Stanley L. Hazen
Objective—The presence of subclinical myocardial necrosis as a prodrome to longer-term adverse cardiac event risk has
been debated. The debate has focused predominantly within patients with acute coronary syndrome, and on issues of
troponin assay variability and accuracy of detection, rather than on the clinical significance of the presence of subclinical
myocardial necrosis (ie, “troponin leak”) within stable cardiac patients. Herein, we examine the relationship between
different degrees of subclinical myocardial necrosis and long-term adverse clinical outcomes within a stable cardiac
patient population with essentially normal renal function.
Methods and Results—Sequential consenting patients (N⫽3828; median creatinine clearance, 100 mL/min/1.73m2)
undergoing elective diagnostic coronary angiography with cardiac troponin I (cTnI) levels below the diagnostic cut-off
for defining myocardial infarction (⬍0.03 ng/mL) were evaluated. The relationship of subclinical myocardial necrosis
with incident major adverse cardiovascular events (defined as any death, myocardial infarction, or stroke) over 3-year
follow-up was examined. “Probable” (cTnI 0.001– 0.008 ng/mL) and “definite” (cTnI 0.009 – 0.029 ng/mL) subclinical
myocardial necrosis were observed frequently within the cohort (34% and 18%, respectively). A linear relationship was
observed between the magnitude of subclinical myocardial necrosis and risk of 3-year incident major adverse
cardiovascular events, particularly in those with cTnI 0.009 ng/mL or higher (hazard ratio, 3.00; 95% confidence
interval, 2.4 –3.8), even after adjustment for traditional risk factors, C-reactive protein, and creatinine clearance. The
presence of subclinical myocardial necrosis was associated with elevations in acute phase proteins (C-reactive protein,
ceruloplasmin; P⬍0.01 each) and reduction in systemic antioxidant enzyme activities (arylesterase; P⬍0.01) but
showed no significant associations with multiple specific measures of oxidant stress, and showed borderline associations
with myeloperoxidase, a marker of leukocyte activation.
Conclusion—In stable cardiology patients, prodromal subclinical myocardial necrosis is associated with substantially
higher long-term risk for major adverse cardiovascular events. The underlying mechanisms contributing to this minimal
troponin leak phenomenon warrants further investigation. (Arterioscler Thromb Vasc Biol. 2010;30:634-640.)

D

etection of circulating cardiac troponins is associated
with the presence of ongoing myocardial necrosis and
fulfills the contemporary definition of myocardial infarction
in the presence of ischemic signs and symptoms.1 The
prognostic role of cardiac troponin levels (either T or I
subtypes) is well-established across the spectrum of acute
coronary syndromes, including within patients with renal
insufficiency and end-stage kidney disease, and serves as a
reflection of myocardial necrosis or stress.2
The presence of “subclinical myocardial necrosis” as a
prodrome to longer-term adverse cardiac event risk has
been debated (ie, “troponin leak”). Some nonischemic
conditions such as renal insufficiency have also been
associated with detection of circulating cardiac troponin

levels,2– 4 particularly in asymptomatic patients with endstage kidney diseases.5,6 In fact, several recent reports have
even associated detectable (but nondiagnostic) cardiac
troponin levels in stable noncardiac subjects in the community with heightened risk for future cardiovascular
events.7–9 At present, it is unclear whether microvascular
ischemic insults, or various oxidative and inflammatory
mediators, contribute to myocyte injury or apoptosis and
progressive myocyte loss, leading to graded release of
troponin fragments into the circulation. Herein, we sought
to examine the phenotype, prognostic significance, and
underlying pathophysiologic mechanisms that may contribute to the development of subclinical myocardial necrosis in stable cardiac patients.

Subjects and Methods
Study Population
The Cleveland Clinic GeneBank study is a large, prospective, cohort
study that established a well-characterized clinical repository with
clinical data and longitudinal outcomes from consenting subjects
undergoing elective diagnostic coronary angiography from 2001 to
2006. All GeneBank participants gave written informed consent
approved by the Cleveland Clinic Institutional Review Board. All
blood samples were collected at the time of cardiac catheterization
procedure, at which time arterial sheath access has been obtained
before diagnostic catheterization or treatment (including heparin).
This analysis included a cohort of 3828 consecutive consenting
subjects without clinical evidence of acute coronary syndrome at the
time of enrollment and is confirmed by including only those with
cardiac troponin I (cTnI) ⬍0.03 ng/mL, no history of revascularization within 30 days before enrollment, and at least 3 years of
adjudicated follow-up data.
We defined coronary artery disease as any clinical history of
myocardial infarction, percutaneous coronary intervention, coronary
artery bypass surgery, or angiographic evidence of significant
stenosis (ⱖ50%) in 1 or more major coronary arteries. Dyslipidemia
was defined as low-density lipoprotein cholesterol ⬎130 mg/dL,
high-density lipoprotein cholesterol ⬍50 mg/dL, or triglyceride
⬎150 mg/dL. An estimate of creatinine clearance was calculated
using the Cockroft-Gault equation, because a majority of subjects
had relatively preserved renal function. Adjudicated outcomes were
prospectively ascertained over the ensuing 3 years for all subjects
after enrollment. Major adverse clinical event (MACE) was defined
as death, nonfatal myocardial infarction, or nonfatal stroke after
enrollment.

high-performance liquid chromatography with online stable isotope
dilution electrospray ionization tandem mass spectrometry, as previously described.14

Statistical Analysis
The Student t test or Wilcoxon rank-sum test for continuous
variables and 2 test for categorical variables were used to examine
the difference between the groups. Because a substantial proportion
of patients had nondetectable cTnI levels (up to 37% of study cohort,
corresponding to the first tertile), the study population was divided
according to approximate tertiles based on cTnI levels rounded to the
nearest 0.001 ng/mL. Unadjusted trends (adjusted for age and gender
only) for all-cause mortality rates as well as nonfatal myocardial
infarction/stroke rates with increasing tertiles of cTnI were evaluated
with the Cochran-Armitage test using a time-to-event approach.
Adjustments were made for individual traditional cardiac risk factor,
Framingham risk factors (including age, gender, cigarette smoking,
low-density and high-density lipoprotein cholesterol, systolic blood
pressure), plus diabetes mellitus, log-transformed hsCRP, and creatinine clearance to predict incident 3-year MACE risks. Logistic
regression models were developed to calculate odds ratios (OR)
associated with the lowest tertile compared with the upper tertiles (ie,
nondetectable vs detectable cTnI). Kaplan–Meier analysis with Cox
proportional hazards regression was used for time-to-event analysis
to determine hazard ratio (HR) and 95% confidence intervals (95%
CI) for MACE. Levels of cTnI were then adjusted for traditional
coronary artery disease risk factors in a multivariable model including
Framingham risk factors, log-transformed hsCRP, and creatinine clearance. We confirmed that both the proportionality hazards and linearity
assumptions were met. All analyses were performed using SAS version
8.2 and R 2.8.0. P⬍0.05 was considered statistically significant.

Subclinical Myocardial Necrosis
Plasma levels of cardiac troponin I were measured using the STAT
Troponin I assay (Abbott Laboratories) in a research-based immunoanalyzer that provides a 3-decimal-point readout from venous
blood samples collected by EDTA tubes. This assay provides highly
sensitive analytic measurement of cTnI with a reported limit of
detection reaching 0.009 ng/mL in the literature, and a diagnostic
cut-off of 0.03 ng/mL for myocardial infarction defined by the upper
limit of normal (99th percentile cut-off with 10% coefficient of
variation).10,11 We confirmed these results by performing ⬎10
replicates of the zero calibrator and 5 replicates of a low-level sample
(target value, 0.035 ng/mL). Mean and SD were determined for each,
and limit of detection was determined at 0.008 ng/mL using the
formula limit of detection⫽2⫻SDlow⫻[measured levels⫼
(Meanlow⫺Meanzero)].12 Based on the analytic characteristics of the
cTnI assay, we defined subclinical myocardial necrosis as “definite” in
the range of cTnI 0.009 to 0.029 ng/mL, “probable” in the range of cTnI
0.001 to 0.008 ng/mL, and “none” if cTnI ⬍0.001 ng/mL.

Biomarkers of Inflammation, Leukocyte
Activation, and Oxidative Stress
High-sensitivity C-reactive protein (hsCRP), ceruloplasmin, myeloperoxidase, and serum creatinine and fasting lipid profiles were all
measured simultaneously with the cTnI assay using the same analysis
platform. Total leukocyte counts were analyzed on the Advia 120
Hematology Analyzer (Siemens). Serum arylesterase activity level was
determined using a modification of a spectrophotometry-based assay as
previously described.13 Briefly, initial hydrolysis rates at 25°C of
phenylacetate substrate (3.6 mmol/L) were determined at 270 nm in
1:50 diluted serum in reactions mixtures comprising 9 mmol/L Tris
hydrochloride, pH 8.0, and 0.9 mmol/L calcium chloride. An extinction
coefficient (at 270 nm) of 1310 mol/L⫺1cm⫺1 was used for calculating
units of arylesterase activity, which are expressed as the amount of
phenyl acetate hydrolyzed in M/min/mL of serum. In a random subset
of subjects (n⫽123), multiple distinct fatty acid oxidation products
(hydroxyeicosatetraenoic acids, hydroxyoctadecadienoic acids, and F2␣isoprostanes) within plasma stored in the presence of antioxidant
cocktail and under inert (argon) atmosphere were determined using

Results
Study Population
The following is the description of reasons for cardiac
catheterization within the study cohort (subjects can have ⬎1
reason per person): history of positive or indeterminate stress
test (50%), evaluation for possible ischemic causes of symptoms (66%), preoperative evaluation (12%), and history of
cardiomyopathy (3%). In our study cohort, 52% of subjects
(1993/3828) had evidence of cTnI detectable below the upper
limit of normal (⬍0.03 ng/mL), including 18% (702/3,828)
with “definite” (cTnI 0.009 – 0.29 ng/mL) and 34% (1291/
3828) with “probable” (cTnI 0.001– 0.008 ng/mL) subclinical
myocardial necrosis. Baseline characteristics of the study
population are shown in Table 1, stratified according to
presence or absence of subclinical myocardial necrosis.
Overall, 68% of subjects had ⱖ50% stenosis at any
coronary artery, 32% of subjects had previous revascularization, and 84% had no subsequent revascularization within 30
days after catheterization. There were no significant differences in the prevalence of none, probable, or definite subclinical myocardial necrosis between these subgroups. However, we observed a trend toward higher rates of any
(probable or definite) subclinical myocardial dysfunction in
those who underwent subsequent revascularization within 30
days of cardiac catheterization compared to those who did not
(61% vs 51%), as well as those with ⱖ50% stenosis at any
coronary artery compared to those without (55% vs 47%).
Only 17% had a history of heart failure and 22% had left
ventricular ejection fraction ⬍50%. Patients with evidence of
subclinical myocardial necrosis were more likely to be older,
with more cardiovascular risk factors and underlying heart
failure/impaired left ventricular ejection fraction, and with

Table 1.

Subject Characteristics
Subclinical Myocardial Necrosis

cTnI range, ng/mL

None (n⫽1835)

Probable (n⫽1291)

Definite (n⫽702)

⬍0.001

0.001– 0.008

0.009 – 0.029

63⫾11

63⫾11

66⫾11

65

69

Demographics and clinical data
Age, y
Male, %

66

History of diabetes mellitus, %

29

31

41*

History of hypertension, %

70

71

75

Cigarette smoking (former/current), %

65/11

64/9

66/10

Previous coronary artery disease, %

68

66

76*

History of heart failure, %

11

15

33*

LV ejection fraction ⬍50%, %

13

23

42*

Maximal stenosis ⱖ50%, %

65

69

Framingham ATP III risk score

76*

13 (11–15)

14 (11–15)

14 (12–16)

LDL cholesterol, mg/dL

95 (78–117)

97 (80–118)

92 (76–112)

HDL cholesterol, mg/dL

34 (28–41)

34 (28–41)

32 (27–40)

Triglycerides, mg/dL

114 (84–162)

115 (84–166)

115 (83–156)

C-reactive protein, mg/L

1.99 (0.91–4.51)

2.11 (0.86–4.58)

2.68 (1.19–6.24)*

Creatinine clearance, mL/min/1.73m2

100 (77–126)

101 (76–126)

Laboratory data

85 (62–113)*

Medications
Aspirin, %

74

73

70

Statin, %

60

58

54

ACE inhibitors, %

44

51

60*

Beta-blockers, %

59

63

63†

Nitrates, %

29

28

32

ACE indicates angiotensin-converting enzyme; ATP III, Adult Treatment Panel III guidelines; cTnI, cardiac troponin
I; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventricular.
Values expressed in mean⫾SD or median (interquartile range).
*P⬍0.01.
†P⬍0.05.

slightly lower renal function at baseline, although overall they
were still within the normal range (Table 1).

Subclinical Myocardial Necrosis and Prognosis
Overall, patients with evidence of subclinical myocardial
necrosis (either probable or definite) were associated with a
2.2-fold increased risk of 3-year incidence of MACE (HR,
2.18; 95% CI, 1.77–2.68; P⬍0.0001) when compared to
those with no evidence of subclinical myocardial necrosis.
When analyzed at the limit of detection cut-off (0.008
ng/mL), those with evidence of subclinical myocardial necrosis still conferred significantly higher risk of death (HR, 2.23;
95% CI, 1.81–2.74; P⬍0.01), nonfatal myocardial infarction,
and stroke (HR, 2.23; 95% CI, 1.81–2.74; P⬍0.01), and
MACE (HR, 2.27; 95% CI, 1.86 –2.76; P⬍0.01) at 3-year
follow-up. After adjusting for traditional risk factors including Framingham risk factors, hsCRP, and creatinine clearance, evidence of subclinical myocardial necrosis (probable
or definite) within stable cardiac patients remained a significant increased risk of incident MACE at 3 years (HR, 1.77;
95% CI, 1.43–2.18; P⬍0.01). Such prognostic value remained significant in various subgroups stratified by age,

gender, presence of diabetes mellitus, or in those with
creatinine clearance ⱖ60 mL/min (but not ⬍60 mL/min).
Also, the results were similar when analyzed only within the
cohort of patients without any subsequent revascularization
over the ensuing 3 years of follow-up (68% of cohort; Table
2). The results also extended to those with no history of heart
failure (adjusted HR for MACE, 2.09; 95% CI, 1.51–2.90;
P⬍0.01), those with preserved (ie, ⱖ50%) left ventricular
ejection fraction (adjusted HR for MACE, 2.83; 95% CI,
1.80 – 4.45; P⬍0.01), and those with statin therapy at baseline
(adjusted HR for MACE, 2.04; 95% CI, 1.43–2.92; P⬍0.01).
There was a noticeable risk increase in those with probable
subclinical myocardial necrosis (cTnI between 0.001– 0.008
ng/mL) vs those without any detectable cTnI (⬍0.001 ng/
mL). This graded risk increase can be clearly illustrated in the
Kaplan–Meier analysis shown in Figure 1. The HR for
adverse cardiac events appear to increase in a nearly linear
fashion above cTnI levels of 0.004 ng/mL (Figure 2). Table 2
demonstrates the relationship between cTnI ranges with
3-year unadjusted and adjusted risks for incidence of death,
myocardial infarction, and stroke, as well as MACE at 3
years, stratified by definite or probable subclinical myocar-

Table 2.

Adjusted HR for Major Adverse Cardiac Events at 3-Year Follow-Up
All Subjects

Subclinical Myocardial Necrosis, n
cTnI range, (ng/mL)

Medically Managed Coronary Disease

None (n⫽1835)

Probable (n⫽1291)

Definite (n⫽702)

None (n⫽894)

Probable (n⫽627)

Definite (n⫽374)

⬍0.001

0.001– 0.008

0.009 – 0.029

⬍0.001

0.001– 0.008

0.009 – 0.029

All-cause death
N of events

96

101

69

72

Unadjusted HR

66
1.0

2.06 (1.51–2.82)*

4.09 (3.00–5.58)*

43
1.0

2.32 (1.58–3.39)*

4.28 (2.93–6.23)*

Age-adjusted/gender-adjusted HR

1.0

1.86 (1.36–2.55)*

3.36 (2.45–4.61)*

1.0

2.06 (1.41–3.03)*

3.56 (2.42–5.24)*

Risk factor-adjusted HR

1.0

1.70 (1.24–2.34)*

2.43 (1.73–3.41)*

1.0

1.96 (1.33–2.87)*

2.90 (1.94–4.35)*

60

41

34

21

Nonfatal MI/stroke
N of events

62

40

Unadjusted HR

1.0

1.76 (1.38–2.25)*

2.92 (2.27–3.76)*

1.0

1.78 (1.32–2.41)*

2.79 (2.06–3.80)*

Age-adjusted/gender-adjusted HR

1.0

1.64 (1.28–2.10)*

2.54 (1.96–3.28)*

1.0

1.62 (1.20–2.19)*

2.40 (1.75–3.28)*

Risk factor-adjusted HR

1.0

1.54 (1.20–1.98)*

1.98 (1.51–2.61)*

1.0

1.56 (1.15–2.12)*

2.04 (1.47–2.84)*

Death/nonfatal MI/stroke
N of events

156

142

103

93

Unadjusted HR

128
1.0

1.74 (1.38–2.20)*

3.00 (2.36–3.81)*

83
1.0

1.80 (1.35–2.40)*

2.88 (2.14–3.87)*

Age-adjusted/gender-adjusted HR

1.0

1.62 (1.28–2.05)*

2.60 (2.04–3.32)*

1.0

1.63 (1.22–2.19)*

2.48 (1.84–3.36)*

Risk factor-adjusted HR

1.0

1.54 (1.21–1.95)*

2.09 (1.61–2.71)*

1.0

1.58 (1.18–2.12)*

2.12 (1.54–2.93)*

MI indicates myocardial infarction.
Values presented as HR and 95% CI in brackets.
Medically managed coronary disease is defined as those with significantly obstructive (⬎50% stenosis at any vessel) coronary disease but without revascularization
within 30 days after catheterization.
*P⬍0.01 and †P⬍0.05 (compared with “none” category): (1) unadjusted; (2) adjusted for age and gender; and (3) adjusted for individual Framingham risk factors,
including age, gender, low-density lipoprotein, high-density lipoprotein cholesterol, systolic blood pressure, smoking, diabetes, creatinine clearance, and
high-sensitivity C-reactive protein.

dial necrosis. Remarkably, the presence of subclinical myocardial necrosis provided superior prognostic value for adverse long-term outcomes compared to other established
cardiac risk factors (Figure 3).
In an effort to better-understand biological processes associated with development of subclinical myocardial necrosis,
we examined the relationship between detectable cTnI levels
and markers of inflammation, leukocyte activation, and systemic oxidative stress (Table 3). In subjects with subclinical
myocardial necrosis, we observed graded and significantly
higher levels in acute phase reactants, such as hsCRP and

Figure 1. Kaplan-Meier analysis for 3-year major adverse clinical
events, stratiﬁed according to deﬁnite (cTnI⫽0.009⫺0.029 ng/mL),
probable (cTnI⫽0.001⫺0.008 ng/mL), and no (cTnI⬍0.001 ng/mL)
subclinical myocardial necrosis.

ceruloplasmin, consistent with heightened systemic inflammation. In contrast, there did not appear to be an association
between levels of cTnI and leukocyte count or plasma myeloperoxidase levels, an index of leukocyte activation. Nevertheless, patients with definite subclinical myocardial necrosis had
significantly higher plasma myeloperoxidase levels compared to
those with no subclinical myocardial necrosis (P⫽0.04) or those
with probable subclinical myocardial necrosis (P⫽0.03). Interestingly, quantification of multiple distinct fatty acid oxidation
products within plasma failed to show any evidence of enhanced

Figure 2. Cubic spline curve of HR for major adverse clinical
events (death, nonfatal myocardial infarction, and stroke) at 3
years with cTnI levels.

those with evidence of subclinical myocardial necrosis (Table 3).
When tested for interaction with baseline statin therapy, only
hsCRP demonstrated significant interaction (P⫽0.014) and
arylesterase activity with borderline significance (P⫽0.05). Cardiac troponin I levels and all other inflammatory and oxidative
biomarkers demonstrated no significant interaction with statin use.

Discussion

Figure 3. Forest plot of risk prediction for major adverse clinical
events at 3 years according to cTnI cohorts in comparison with
standard cardiovascular risk factors in multivariable Cox proportional hazard analysis. Major adverse clinical events deﬁned as
death, nonfatal myocardial infarction, and stroke over the ensuing 3 years of follow-up. CrCL indicates creatinine clearance.

oxidant stress among subjects with vs without evidence of
subclinical myocardial necrosis (Table 3). However, serum
levels of arylesterase activity, a cardioprotective antioxidant
activity catalyzed by the high-density lipoprotein associated
protein paraoxonase-1,7 were significantly (P⬍0.01) lower in

Myocardial necrosis is considered the primary consequence of
ischemia during acute coronary syndromes and provides not
only robust prognostic value but also clinical indication for
therapeutic interventions. Over the years, improved recognition
of assay limitations, as well as detection of a subset of patients
with a “troponin leak” below the standard diagnostic range, has
emerged. Discussions regarding the clinical utility of cardiac
troponins in plasma have focused on analytic precision and
accuracy, and revised definitions of 99th percentile cut-off values
among apparently healthy subjects have been proposed as the
upper limit of normal for diagnostic purposes.15 The prognostic
utility of detecting a “troponin leak” below this cut-off has been
debated and, correspondingly, whether pathophysiologic mechanisms are at play leading to detection of a “subclinical cardiac
troponin leak” has remained unclear. Moreover, the clinical
necessity of improved sensitivity cardiac troponin assays has
also been intensively debated because few studies have examined the clinical prognostic value, particularly among stable
patients, or with use of a central reference laboratory and a
high-sensitivity assay capable of monitoring levels below the

Table 3. Inflammatory and Oxidative Biomarkers in Subgroup Stratified by Presence of
Subclinical Myocardial Necrosis
Subclinical Myocardial Necrosis
Biomarkers

None (n⫽1835)

Probable (n⫽1291)

Definite (n⫽702)

P

1.71 (0.84–3.81)
22 (19.0–25.6)

2.11 (0.86–4.59)

2.68 (1.19–6.25)

⬍0.01

23.2 (20.3–27.4)

24.2 (20.8–28.1)

⬍0.01

Acute-phase reactants
C-reactive protein
Ceruloplasmin
Leukocyte activation
Total leukocyte count

6.1 (5.0–7.4)

6.0 (5.0–7.2)

6.2 (5.0–7.5)

0.78

Myeloperoxidase

98 (68–193)

102 (71–186)

113 (78–221)

0.07

103 (87.8–120.5)

95.5 (79.7–113.8)

Antioxidative pahways
Arylesterase activity
Oxidative fatty acids

105.2 (89.6–123.4)
(n⫽33)

(n⫽61)

⬍0.01

(n⫽29)

5-HETE

14.7 (9.6–20.3)

12.8 (8.8–20.1)

15.3 (12.0–21.0)

0.91

8-HETE

2.2 (1.6–3.0)

2.1 (1.3–3.1)

2.5 (1.7–3.4)

0.53

9-HETE

29.2 (18–42.9)

24.6 (16.5–42.6)

33.0 (22.0–43.9)

0.28

11-HETE

5.05 (4.05–5.94)

4.57 (3.47–6.29)

4.80 (3.38–6.20)

0.37

12-HETE

6.62 (5.07–8.50)

5.77 (3.94–9.05)

6.18 (4.97–8.20)

0.79

15-HETE

22.2 (14.5–27.4)

18.1 (11.6–26.7)

19.9 (10.8–25.5)

0.36

9-HODE

29.3 (22.9–35.1)

27.3 (16.9–38.6)

28.6 (16.8–37.7)

0.74

13-HODE

31.5 (23–38.8)

28.2 (18.7–43.8)

28.5 (17.8–40.5)

0.48

6.1 (1.7–15.6)

7.4 (2.7–15.8)

0.46

8-isoPGF2␣

7.9 (2.0–18.5)

8-iso PGF2␣ indicates 8-isoprostane prostaglandin F2␣; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyloctadecadienoic acid; all expressed in pM/mL.
*All levels expressed in median (interquartile range).
P by ANOVA.

Tang et al

Troponin Leak As a Prodrome to Adverse Cardiac Events

classic clinical threshold for diagnosis of an ischemic event. Our
observations provide strong support for the concept that any
detectable cTnI level heralds enhanced long-term adverse cardiovascular event risk. We also demonstrated that within the
cohort with detectable subclinical myocardial necrosis, there
were heightened inflammatory and reduced antioxidative processes, even though there was only borderline evidence of
significant leukocyte activation and no evidence of enhanced
systemic indices of oxidant stress. The findings of heightened
cardiovascular risk at levels equal or greater to traditional
cardiovascular risk factors are consistent with recent report using
a high-sensitivity cardiac troponin T assay16 and support the
notion that detection of any cTnI within plasma warrants more
globally aggressive risk reduction efforts and closer long-term
monitoring because this represents a high-risk group of patients.
It also suggests that therapeutic efforts at reducing cTnI leak and
incident development of future adverse cardiovascular events in
this group should also be considered.
Our data significantly extend the clinical information available about detection of subclinical myocardial necrosis in multiple aspects. Recent registry data have suggested the prognostic
value of detectable levels of cardiac troponin (thus far determined qualitatively as above the “upper limit of normal”) in
patients, such as those presenting with acute decompensated
heart failure for detecting in-hospital mortality,17 or in those
undergoing percutaneous coronary intervention for detecting up
to 1-year mortality risk.18 Instead, our study focused entirely on
individuals with cTnI levels below the upper limit of normal and
on a large number of subjects without any subsequent coronary
revascularization. The large, single-center cohort experience of
stable subjects undergoing cardiac evaluation allows careful
description of a study cohort regarding their selection, stability,
and degree of atherosclerotic burden. The advantage of analyzing cTnI levels with the same assay in a core reference
laboratory using a research-based immunoanalyzer allows the
opportunity to quantify long-term risk beyond a dichotomous
categorization of “positive” vs “negative” level (ie, above vs
below the limit of detection) grossly utilized in published
literature on this topic. A clear dose–response relationship for
increased risk and relatively tight CI was observed within our
cohort (Figure 2). The availability of traditional clinical and
biochemical risk markers for multivariable adjustments also
strengthen the support of the independent added clinical significance of detecting the presence of subclinical myocardial
necrosis.
One of the more remarkable observations in the present
study is how pervasive “troponin leak” is within a stable
cardiology patient population. Almost half of the cohort had
detectable cTnI levels, among which 65% were within the
“probable” range (0.001– 0.008 ng/mL). Of interest, only
approximately one-third (37%) of patients with measurable
plasma cTnI levels also demonstrated significant (ⱖ50%
stenosis in ⱖ1 major vessels) obstructive coronary artery
disease on coronary angiography, suggesting the other twothirds of subjects are at increased risk; however, this would
not be observed using traditional risk stratification methods
or invasive testing that relies on significant luminal narrowing (ie, most imaging methods). Whereas evidence of macrovascular ischemia as a contributor to the observed troponin
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leak seems remote, the presence of vulnerable plaque with
microvascular ischemic insults or microembolisms may be
more prevalent than previously appreciated and serve as a
contributory mechanism to the development of subclinical
myocardial necrosis. The concomitant presence of heightened
inflammatory and reduced antioxidative processes among
subjects with subclinical myocardial necrosis suggests the
potential for some common underlying pathophysiologic
processes at play. Interestingly, our results did not identify
differences in systemic levels of leukocytes or elevations in
multiple distinct oxidized fatty acid species, and identified
only borderline associations with myeloperoxidase levels, a
marker of leukocyte activation. These results may suggest
that the pathophysiologic process leading to subclinical myocardial necrosis may be regional or partially independent of
leukocyte-mediated progression of disrupting vulnerable
plaques, as seen in macrovascular ischemia.
The prognostic value in the “borderline” range of cTnI may
vary widely depending on which assay is being used.19 There are
several potential interferences that may influence circulating
levels of cTnI, including the presence of heterophile antibodies
or other noncardiac confounders such as renal insufficiency.10,20,21
The prevalence of 18% with definite subclinical myocardial
necrosis (0.009 – 0.29 ng/mL range) in our study population is
comparable with some but not all previous reports in the
literature (up to 22% in an elderly population with ⬎0.01 g/L
by Beckman Coulter Access AccuTnI assay in a European
cohort22). In particular, detectable cardiac troponin T levels in
otherwise healthy elderly subjects was also associated with
poorer long-term prognosis (even though only 4% of that
specific population had detectable levels).7 Whether the detection of subclinical myocardial necrosis can allow therapeutic
targeting of potential modifiable risk factors for reversal or delay
of the progression of disease processes remains to be determined. Further investigations are warranted regarding the potential for aggressive preventive strategies based on identification of
an at-risk population defined by the presence of subclinical
myocardial necrosis.

Study Limitations
A strength of the present study is that the study cohort is an
aggressively treated cardiology population in the modern era of
high-potency statin therapy. However, this also leads to a clear
selection bias in the study population because they were deemed
to have enough clinical suspicion (either by positive or equivocal
stress test results or clinical presentation) to warrant an elective
diagnostic invasive coronary angiographic evaluation. The diagnostic range of cTnI levels used in this study overlaps with a
majority of otherwise “healthy controls,”10 which argues to the
broader potential generality of the present findings beyond the
relatively higher-risk population examined in the present clinical
setting. Such low ranges are not routinely reported in standard
laboratory evaluations, and their accuracy and reproducibility
have not been extensively evaluated even though their sensitivities have been comparable to other sensitive cardiac troponin
assays.23

Conclusion
In stable patients undergoing elective cardiac evaluation,
detectable cTnI levels by high-sensitivity assay are com-

monly observed despite being well below the consensusdefined diagnostic range. The present studies indicate that
subclinical myocardial necrosis is a relatively common pathophysiologic phenomenon in the cardiology patient setting,
and that detection of any cTnI within plasma may provide
independent risk prediction of near-term and long-term adverse clinical events.
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